^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    leucovorin calcium

    Company:
    Generic mfg.
    Drug class:
    Folate analog
    Related drugs:
    1d
    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    1d
    SYNCHRONOX: FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases (clinicaltrials.gov)
    P=N/A, N=550, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    1d
    A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    2d
    FOXHIPECT4: Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer (clinicaltrials.gov)
    P3, N=1083, Recruiting, Maimónides Biomedical Research Institute of Córdoba | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • mitomycin
    2d
    A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov)
    P2, N=60, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    2d
    Efficacy and safety of drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in unresectable gastric cancer with liver metastasis. (PubMed, Ther Adv Med Oncol)
    Patients underwent 135 sessions using either HepaSphere beads plus HAIC-FOLFOX (HEPA-HAIC, n = 33) or DC bead plus HAIC-FOLFOX (DCB-HAIC, n = 29)...Nausea, vomiting, and severe pain were significantly less frequent with HEPA-HAIC (5.6% vs 31.7%, p = 0.001; 4.2% vs 31.7%, p < 0.001; 8.3% vs 22.2%, p = 0.01). DEB-TACE plus HAIC was feasible and demonstrated intrahepatic disease control with acceptable tolerability in unresectable GCLM; HEPA-HAIC showed a favorable safety profile.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    5-fluorouracil • leucovorin calcium • DC Bead (E7040)
    3d
    UC-GIG-2515: Liver-directed chemotherapy after surgery of liver metastases of colorectal cancer in patients withnhigh risk of recurrence of their disease. (2025-523913-27-00)
    P2/3, N=272, Not yet recruiting, Unicancer
    New P2/3 trial
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • levoleucovorin calcium
    5d
    A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC (clinicaltrials.gov)
    P3, N=280, Recruiting, Sun Yat-sen University | Unknown status --> Recruiting | Trial completion date: Dec 2018 --> Dec 2026 | Trial primary completion date: Dec 2017 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium
    5d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    5d
    ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Mar 2026 --> Sep 2027 | Trial primary completion date: Mar 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598
    5d
    Conversion and resection rates in borderline resectable and locally advanced pancreatic cancer following neoadjuvant therapy: a retrospective multicenter cohort study. (PubMed, Front Oncol)
    Analyzed variables included demographics, tumor characteristics (location, stage), NAC regimens (FOLFIRINOX, GEMCAP, gemcitabine monotherapy), response to therapy (RECIST criteria), surgical outcomes (resection rate, R0 resection), CA19-9 levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and survival outcomes (overall survival (OS) and progression-free survival (PFS))...Elevated pre-treatment CA19-9, NLR, and PLR may identify patients less likely to benefit from NAC. Biomarker-driven trials are warranted to optimize patient selection and personalize treatment strategies, especially in resource-constrained settings.
    Retrospective data • Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium
    5d
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=267, Recruiting, Pfizer | Trial completion date: Aug 2030 --> Oct 2029 | Trial primary completion date: Feb 2029 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    BRAF V600E • MSI-H/dMMR
    |
    Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • claturafenib (PF-07799933) • midazolam hydrochloride